Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety study of pegfilgrastim via on-body injector in breast cancer
jRCT2080225037Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegfilgrastim in breast cancer and chemotherapy-induced neutropenia (CIN), sponsored by Kyowa Kirin. Primary endpoint: Safety of pegfilgrastim via on-body injector. Started Jan 2020; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
breast cancerchemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on jRCT2080225037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225037.